Dienstag, 27. September 2011

Diskutieren Sie mit Patrick Langecker - Leiter Multichannel Management der Bayer Vital GmbH

Patrick Langecker leitet seit Januar 2011 das Team Multichannel Management bei der Bayer Vital GmbH in der Business Unit General Medicine. In diesem neu geschaffenen Team geht es um die geschäftsnahe Vernetzung aller möglichen Kommunikationskanäle zum Kunden in Ergänzung zum Außendienst. Zuvor war er zwei Jahre im Bereich Marketing and Sales Innovations als Leiter Dialogmarketing businessübergreifend tätig. Von 2005 bis 2008 war er für die Endkundenansprache im Marketing von Diabetes Care der Bayer Vital verantwortlich. Vor seiner Zeit bei Bayer arbeitete er als CRM- und Dialogexperte für internationale Konzerne im Finanzdienstleistungs-, Reise- und Automobilbereich, sowie für große Servicedienstleister.

Auf der Pharma Sales Force 2011 wird Patrick Langecker die interaktive Brainstorming Session zu Closed Loop Marketing moderieren. Nutzen Sie die Möglichkeit zum informellen Erfahrungsaustausch. Diskutieren Sie in kleinen Gruppen aktuelle Herausforderungen und Perspektiven im Pharmavertrieb und profitieren Sie vom Wissen unserer Branchenexperten. Bringen Sie eigene Ideen und Erfahrungen ein und tauschen Sie sich mit anderen Teilnehmern in einem offenen Diskussionsforum aus!

Mehr Informationen zu dem Jahresforum und den Brainstorming Sessions finden Sie hier.



Dienstag, 20. September 2011

Free whitepapers on Pharmacogenomics and Drug Transporters


Access free whitepapers on Pharma Imaging and Modelling for Optimized Translational Research; for example articles on Pharmacogenomics and Drug Transporters:


Pharmacogenomics - Drug Disposition, Drug Targets, and Side Effects
It is well recognized that different patients respond in different ways to the same medication. These differences are often greater among members of a population than they are within the same person at different times (or between monozygotic twins).

Drug Transporters in ADME
Pharmaceutical companies are investing research time into understanding and modelling of drug transporters to better predict drug-drug interactions and toxicities. Whilst understanding drug-drug interactions can enhance study efficiency and drug efficacy, the challenges presented by drug transporters are complex.

Access more at:  Imaging and Modelling for Optimized Translational Research

Montag, 19. September 2011

Video: Market Access und Stakeholder Management in der Pharmaindustrie

Isabel Henkel, Director Access & Reimbursement, Johnson & Johnson Medical GmbH, exklusiv im Interview!

Frau Henkel spricht über die neuen Aufgaben für die Pharmaindustrie im Bezug auf Market Access und Stakeholder Management sowie die vierte Hürde im deutschen Gesundheitssystem.

Sehen Sie das gesamte Video hier.



Mittwoch, 14. September 2011

Optimizing drug discovery through microdosing

Defining a microdose
The EMEA Position Paper defines the human microdose as the 1/100th of the dose calculated to yield a pharmacological effect of the compound based on primary pharmacodynamic data obtained from animal and in vitro models. According to the EMEA guidelines, the total amount of drug compound(s) being tested and administered in a human microdosing study must not exceed 100 micro grams.

Microdosing in optimizing drug discovery
Advances in areas of combinational chemistry, molecular and cell biology, high throughput technology and strong economic forces have lead to greater competition and rapid changes in nonclinical drug development. Patients, physicians and pharmaceutical sponsors alike are looking for more effective and safer medicines to be developed faster and also have improved costeffectiveness (Lesko et al., 2000).

Reigner et al. (1996) have explained that predictive power of preclinical drug metabolism has advanced due to a considerable betterment in the  understanding of the relationships between in vitro, animal and human pharmacokinetics. They further emphasize that focussed application of pharmacokinetics and pharmacodynamics has improved the efficacy of the drug development process in the pharmaceutical industry. Microdosing  has proven to be an effective method to understand the pharmacokinetic and pharmacodynamic  behaviour of new drugs in humans.

Microdosing has hastened the pharmaceutical preclinical to clinical translation involved in the drug development process. Pang, Rodrigues and Peter (2009, p. 363) elucidate that microdosing has not been developed to determine the safety or efficacy of test compounds when administered to humans. The main purpose of human microdosing studies is to determine key pharmacokinetic parameters in reaction to very small doses of a new drug being tested.

Advent of microdosing
Drug discovery is a long drawn process that involves preclinical pharmacological testing and clinical application in animals and then humans, before drugs can be certified for normal dosage and prescription. Considering the fact that microdoses help decipher the pharmacokinetics in humans for varied newly developed pharmaceutical compounds, large amount of resources in the form of time, energy and money need not be invested into a new drug candidate that is unsuccessful at this level itself.

As a matter of fact, around 40% of the newly developed drugs are withdrawn after phase 1 clinical trial because of undesirable pharmacokinetic properties (Lappin and Garner, 2003). Accordingly, a phase 0 testing has been introduced before the traditionally followed phase 1 clinical trial in humans. Through this, microdosing can be performed in human volunteers in phase 0 following minimal trials in animals. Based on the performance and pharmacokinetic behaviour during this stage, failure drugs can be easily identified and eliminated at the earlier stages without wasting much of time and energy in further drug development and testing, On the other hand, microdosing also helps identify the more promising drug compounds from a pool that could be further explored and developed to achieve desired clinical results in humans when they are tested at later stages of drug development. Sarapa (2003) highlights that two of the most important positive outcomes of performing phase 0 studies by administering microdoses to humans are the reduction in time  and resources wasted in prolonged further testing and reduced attrition during drug testing.

Concentration of microdoses
A microdose is usually 100 times less concentrated than the medication that would be administered once tested and verified. This way the concentration of the newly developed drug entering the human system would be well less than 1/100 concentration of the drug. This is less liable to produce any harm to the human volunteers during testing.

Microdosing procedure
Selecting candidates for human microdosingPharmacological activity is first studies in animal models. Based on this demonstration and minimal animal testing, it is decided whether or not to proceed with clinical trials in humans. Accordingly, candidates for the human microdosing study are selected.

>> Read more on:
  • Microdose synthesis
  • Administration of Human microdose
  • Bio analysis post microdosing
  • Advantages of Microdosing
  • Limitations of Microdosing
  • Microdosing in drug development
  • Regulations for microdosing
  • Conclusion

Download the full 7-page PDF article for free, click here.

Want to learn more about drug discovery?
Visit our Download Center for more articles, whitepapers and interviews:
http://bit.ly/preclinical-clinical-translation

Dienstag, 13. September 2011

Tackling the Challenge of Serialisation and Traceability

As counterfeit drug sales become increasingly costly to both pharmaceutical manufacturers and patients, companies are attempting to address the challenges of serialisation and traceability to reduce the burden on health services across the world. There is already a great degree of activity in the industry to help boost supply chain security, reduce counterfeiting and ultimately protect patient safety and companies' bottom lines, and one company which is aiming make a difference in the sector is Belgian firm Zetes.

The coding systems company has already is predicted a "very good financial year" after revenues rose by almost six per cent in the first half of 2010, largely due to sales in its Goods ID division, which focuses on technologies used to manage products through the supply chain using barcodes, RFID and voice recognition systems. In its interim results statement, the firm revealed that although much of Zetes Goods ID division sales come from the food sector, it has begun to make forays into the pharmaceutical sector and has ambitious plans with regards to serialisation and traceability.

"From a sector perspective, the distribution sector and the pharmacy sector are the ones supporting the growth," the company stated. At the start of the month, Zetes' expanded its activities in the pharmaceutical sector by launching a new datamatrix marking, control and serialisation solution which it claims will "help drug manufacturers across Europe comply with new and incoming legislation regarding the identification of secondary packaging of medical goods". The solution ensures the accurate affixing of datamatrix codes, either directly on the package (coding or marking) or via real-time printed labels, which is designed to  minimise the chances of counterfeiting occurring. In addition, the tool also handles serialisation, tamper-evident sealing, and labelling with pre-printed labels, with Zetes claiming it has been designed to integrate with high speed production lines, which will ensure secure marking and inspection and the storage of data of up to 500 packs per minute.

Alain Wirtz, chief executive of Zetes, said that improving traceability is an "increasing challenge" for many manufacturers, with one drug manufacturer in France already utilising the news system to print the datamatrix codes needed to comply with the country's CIP13 batch-level coding requirements. He explained: "Our solution has been developed based upon our extensive experience with designing, building and implementing print and labelling systems, which are already used by many drug manufacturers at the end of their  production lines." Mr Wirtz said that the counterfeiting of medicinal products is an "increasing threat to public health and safety", and pointed out that the European Federation of Pharmaceutical Industries and  Associations is working on an end-to-end product verification system, based on mass serialisation.

By identifying each individual product, he noted that the industry may be able to combat counterfeiting, reduce theft and derivations, and thus ensure improved patient safety. With industry leaders keen to identify the best way of achieving a smooth transition to mass serialisation and keep apace of the rapidly-evolving  authentication, serialisation and track and trace systems in order to reduce counterfeiting and remain competitive, developments such as those being made by Zetes are likely to continue to increase in volume in the coming months and years.

Cost-effective supply chain security and compulsory safety features are industry buzzwords and both will play a key role in serialisation and traceability in the near future.

Want to learn more about developments and technologies in pharmaceutical authentication?
Visit our Download Center for more articles, whitepapers and interviews:
http://bit.ly/track-and-trace

Mittwoch, 7. September 2011

Der Pharma-Markt nach dem AMNOG

Yvonne Bruchhausen, Leiterin Key Account Solutions bei GlaxoSmithKline Deutschland, sprach exklusiv mit IQPC über den aktuellen Status bei Direktverträgen, entscheidende Kriterien für erfolgreich abgeschlossene Verträge, und wie sich der Markt durch das Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) verändern wird. Das AMNOG soll künftig direkte Verhandlungen von Herstellern und Kassen ermöglichen.

Das Interview wurde als Video aufgezeichnet. Starten Sie das Video hier.

Dienstag, 6. September 2011

Current legislative and regulatory infrastructure - in the context of pharmaceutical product tracking

In present times, legislative and regulatory measures are of great importance in the pharmaceutical industry. We always take it for granted that pharmaceutical products around us are appropriately manufactured, properly labelled and safe for consumption. This trust is due to the fact that we believe these pharmaceutical products are manufactured and tested under strict regulations and laws formed by the government. It is only this way they can reach the patient or the end user. However, this view is quite far from the real truth. The real legislative and regulatory infrastructure was first given proper shape in 1927 when the FDA (Food & Drug Administration) was formed. These days one of the most important aspects concerning pharmaceutical industry is pharmaceutical product tracking and the laws and regulations dealing with this aspect. A good and efficient system meant for tracking and tracing pharmaceutical products will eventually help in detecting the counterfeit medicines. Moreover, this system also helps in a better control of supply chain and also the proper identification of pharmaceutical products even if recalls are required. However, counterfeit medicines are by and large still the biggest challenge to be dealt with. It is to be noted that fraud and counterfeiting are the most risky factors when we are talking about the safety of pharmaceuticals.

Developments in pharmaceutical product tracking in the USA

In the year 2004, the FDA, in its first report dealing with the problem of counterfeit drugs, emphasised the importance of electronic track & trace technology to ensure the safety of the supply of medicines. The FDA implemented the use of RFID (Radio Frequency Identification) technology to be the standard technology in tracking and tracing pharmaceutical products in 2007. RFID is a kind of technology which by using radio frequencies allows the automatic identification & data capture of a product. Under this technology, usually a unique or an exclusive type of identifier and some additional information is attached with the product using a device called as microchip.

This information can be read and interpreted by using a wireless device called an RFID reader, which uses radio frequencies to read an electronic tag attached to the product and identifies this unique identifier. However, implementing such a system in the pharmaceutical industry, some basic industry standards, as well as the necessary IT infrastructure first had to be set up. The RFID system will now be implemented under the Prescription Drug Marketing Act (1987). Although strongly favoured by the FDA and the US pharmaceutical industry, there are some issues involved with using RFID technology. First of all, it is quite costly and another issue is regarding the patient’s privacy. Further, in the USA, some medicines are packed in smaller packs by the pharmacists and in these cases a bar code system and RFID does not allow total control of the product. In Europe, there is a unit of use pack which allows the total control of the supply chain. Moreover, most companies are still hesitant in attaching the RFID tags to pharmaceutical products as they are still waiting for maturing of technical standards. The war against the counterfeit medicines is slowly shifting into full gear in the USA, as the government has also formed a new law making this counterfeit medicines issue a criminal offence with the offender facing punishment of up to life imprisonment, depending on the severity of patient suffering.

Product tracking for supply chain efficiency and protection

In present times, pharmaceutical companies and regulatory agencies are very concerned about fraud and counterfeiting issues in the whole supply chain network especially when the medicines are getting expensive. The government plays a very important role in protecting people from counterfeit drugs by introducing regulations and laws covering the whole pharmaceuticals supply chain which puts a check at each and every stage, starting right from the production facility. In the last five years, the technology used for tracking pharmaceutical products has been developed and upgraded many times due to technological advancements. This has led to many possibilities like tracing and tracking these products down to an item level. RFID technology, scanning technology, 2D matrix codes and sophisticated databases have enormously helped in offering more accountability all over the supply chain.

Therefore, the emergence of track & trace systems for drugs is becoming a necessity and due to this reason this has become a legal requirement in many countries. Different methods are given importance in different countries depending on the requirements and packaging standards of drugs. While in Europe 2D data matrix codes are given preference, in the USA, RFID technology is the preferred one. It is to be noted that RFID is considered to have more advantages than the other technologies as it can also monitor other conditions like temperature when drugs are transported from one place to another. So in order for the supply chain to be robust, these tracking and tracing technologies have to be in place.

Download the full article for free:

Handling des Datenvolumens im 2-SM
Current legislative and regulatory infrastructure - in the context of pharmaceutical product tracking
Depending upon the various types of drug packs and formats, there are various problems associated with the tracking and tracing of pharmaceutical products especially when tracking a single item. In Europe, blister packs are used, while in the USA containers of tablets are used and the information is coded on the container, not on a per item kind of basis.

Freitag, 2. September 2011

Effective Information Management to Aid Regulatory Submissions


Konferenz Regulatorisches (e)Dokumentenmanagement Pharma
 
Article
Effective Information Management to Aid Regulatory Submissions: What Do You Do to Make it Work in Practice?
Pharmaceutical companies are placing even more importance on the pharma regulatory aspects of data and information systems. Neil Gow, Head of Records Management for UCB, joins us to discuss the challenges to efficient and effective mnagement in pharma and biotech.

Read the full article HERE !

Donnerstag, 1. September 2011

Pharma Sales Force: Rückblick & Eindrücke aus 2010

Zum sechsten Mal fand die Pharma Sales Force im Oktober 2010 in Berlin statt. Über 100 Teilnehmer haben die Pharma Sales Force 2010 genutzt, um sich über aktuelle Herausforderungen im Pharmavertrieb auszutauschen.

Informationsreiche Kongresstage
Mehr als 30 Fachvorträge, Round-Table-Diskussionen und Workshops zu den Themen Market Access, Marketing und Vertrieb boten die Möglichkeit zum Benchmarking der eigenen Konzepte und Strategien.




Intensives Networking
Wie gewohnt kam auch das Networking nicht zu kurz: Der Kongress bot zum offenen Austausch ausgiebige Gelegenheiten an. Und auch im Anschluss konnten Themen und Gespräche in angenehmer Atmosphäre vertieft werden.



Kundenstimmen

"Wenn du Sales-Verantwortung hast – hingehen!"

Michael Esther, Verkaufsleiter Deutschland BU Onkologie & Hospital, Riemser Arzneimittel AG


"Hochwertige Konferenz mit vielen Entscheidern, die fest in unserem Marketingplan gebucht ist"

Roger Schramm, Account Executive Retail & Manufacturing, SPSS GmbH

"Geballtes Know-how auf hohem Niveau."
Matthias Diessel, head of Business Development, easyApotheke AG
------------------------------------------------------------------------

Mehr Eindrücke von der Pharma Sales Force 2010 gibt es in dem Impressionen-Video.

Sie wollen die Pharma Sales Force 2011 auf keinen Fall verpassen? Mehr Informationen sowie das exklusive Programm finden Sie hier.